Evidence map›Paper›PMID 32457494›Full record

ReviewNature reviews. Rheumatology2020

Kawasaki disease: pathophysiology and insights from mouse models.

Magali Noval Rivas, Moshe Arditi

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 185 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
185citing papers in PubMed, 6 pooled it
30.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

185 citing papers in PubMed, 6 syntheses or guidelines pooled it, 289 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

125 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Magali Noval RivasDepartments of Pediatrics, Division of Infectious Diseases and Immunology, and Infectious and Immunologic Diseases Research Center (IIDRC), Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. magali.novalrivas@csmc.edu.ORCID http://orcid.org/0000-0001-5570-8928
Moshe ArditiDepartments of Pediatrics, Division of Infectious Diseases and Immunology, and Infectious and Immunologic Diseases Research Center (IIDRC), Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Moshe.Arditi@cshs.org.ORCID http://orcid.org/0000-0001-9042-2909
Cedars-Sinai Medical Center · US

Funding

Role of IL-1 in Bacterial ligand-induced vasculitis and myocarditisR01AI072726 · NIAID · CEDARS-SINAI MEDICAL CENTER · PI ARDITI, MOSHE · 2008 to 2020
$4.5M
Role of intestinal microbiome and gut permeability in the development of Kawasaki Disease vasculitisR01HL139766 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI Magali Noval Rivas · 2018 to 2026
$3.4M
NHLBI NIH HHS R01 HL139766NIAID NIH HHS R01 AI072726
6 · The paper itself

Abstract

Kawasaki disease is an acute febrile illness and systemic vasculitis of unknown aetiology that predominantly afflicts young children, causes coronary artery aneurysms and can result in long-term cardiovascular sequelae. Kawasaki disease is the leading cause of acquired heart disease among children in the USA. Coronary artery aneurysms develop in some untreated children with Kawasaki disease, leading to ischaemic heart disease and myocardial infarction. Although intravenous immunoglobulin (IVIG) treatment reduces the risk of development of coronary artery aneurysms, some children have IVIG-resistant Kawasaki disease and are at increased risk of developing coronary artery damage. In addition, the lack of specific diagnostic tests and biomarkers for Kawasaki disease make early diagnosis and treatment challenging. The use of experimental mouse models of Kawasaki disease vasculitis has considerably improved our understanding of the pathology of the disease and helped characterize the cellular and molecular immune mechanisms contributing to cardiovascular complications, in turn leading to the development of innovative therapeutic approaches. Here, we outline the pathophysiology of Kawasaki disease and summarize and discuss the progress gained from experimental mouse models and their potential therapeutic translation to human disease.

Indexed as

AnimalsCalcium SignalingChildCoronary AneurysmCytokinesFemaleGene Expression ProfilingHumansImmunity, InnateImmunoglobulins, IntravenousInterleukin-1betaMaleMatrix MetalloproteinasesMiceMice, Inbred C57BLMicroRNAsCytokinesImmunoglobulins, IntravenousInterleukin-1betaMatrix MetalloproteinasesMicroRNAs

Identifiers

PMID32457494
PMCPMC7250272
OpenAlexW3032564210

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.